Mstn-ant1

Mstn-ant1 is a **recombinant protein-based myostatin inhibitor** that functions as a dominant negative antagonist of myostatin (also known as growth differentiation factor 8 or GDF8). Specifically, Mstn-ant1 is a C-terminal truncation of the myostatin protein, typically encompassing amino acids 266-350 of the myostatin sequence. By mimicking part of the endogenous myostatin structure while lacking full biological activity, Mstn-ant1 competitively inhibits signaling by endogenous myostatin, thus counteracting its negative regulation of skeletal muscle growth. Mstn-ant1 has been researched primarily in preclinical and experimental settings for its ability to increase proliferation and differentiation of myoblasts, and to suppress muscle atrophy and DNA damage induced by myostatin in cellular and animal models[3][5]. Its primary proposed indication is in conditions characterized by muscle wasting or impaired regeneration, such as muscular dystrophies, age-associated sarcopenia, and possibly diabetes-associated muscle loss. There is no evidence that Mstn-ant1 is being developed or marketed by a pharmaceutical company or that it has reached clinical trials in humans; its use is thus limited to laboratory research.

Other names

Mstn-ant1Mstn-ant-1Mstn-ant 1